Provided by Tiger Trade Technology Pte. Ltd.

3SBIO

15.540
-0.610-3.78%
Volume:35.81M
Turnover:559.08M
Market Cap:39.29B
PE:3.88
High:16.120
Open:16.120
Low:15.480
Close:16.150
52wk High:36.264
52wk Low:14.594
Shares:2.53B
HK Float Shares:2.53B
Volume Ratio:2.41
T/O Rate:1.42%
Dividend:0.26
Dividend Rate:1.69%
EPS(LYR):4.007
ROE:35.88%
ROA:22.68%
PB:1.22
PE(LYR):3.88
PS:1.88

Loading ...

3SBio Allocates HK$62.6 Million to Buy Back 4 Million Shares

Stock News
·
2 hours ago

3SBio Files HKEX Next-Day Disclosure Return Reporting Share Repurchase

Reuters
·
2 hours ago

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Stock News
·
Yesterday

3SBio Repurchases 1.50 Million Shares for HK$23.59 Million

Bulletin Express
·
Sep 02

3SBIO Uses HK$23.6 Million in Share Buyback on September 2

Stock News
·
Sep 02

3SBio Files HKEX Next-Day Disclosure Return Reporting Share Buyback at HKD 15.72

Reuters
·
Sep 02

CLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating

Stock News
·
Aug 31

Movement Alert|3SBIO Falls 5.07% in Regular Trading, Pfizer BD Deal Lands with 17% Discount Share Placement Sparking Dilution Concerns

Market Focus
·
Aug 31

CICC Keeps Outperform Rating on 3SBIO, Trims Target Price to HK$30.00

Stock News
·
Aug 24

3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline

Simply Wall St.
·
Aug 21

3SBio H1 FY26 Net Profit Rises 26.5% to RMB 1.44 Billion; Revenue Increases 3.9% to RMB 4.53 Billion

Reuters
·
Aug 21

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Dow Jones
·
Aug 21

Morning Market Pulse: Hang Seng Index Climbs 0.72% in Early Session, Lithium Miners Lead Gains

Stock News
·
Aug 21

Hong Kong Stock Alert: 3SBIO Surges Over 7% on Strong First-Half Adjusted Operating Profit Growth

Stock News
·
Aug 21

Movement Alert|3SBIO Rises 5.58% in Regular Trading, H1 Adjusted Profit Up 26.5% and New Drug Approval Boost Sentiment

Market Focus
·
Aug 21

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Dow Jones
·
Aug 21

China's 3SBio H1 Net Profit Falls on Higher Expenses

Reuters
·
Aug 20

3SBio H1 Revenue RMB 4,526 Million

THOMSON REUTERS
·
Aug 20

China National Medical Products Administration: Approves 3S Guojian's Nonsteroidal Anti-Inflammatory Drug

THOMSON REUTERS
·
Aug 20

Movement Alert|3SBIO Rises 5.15% in Regular Trading, Interim Results Review and Biotech Sector Strength Fuel Gains

Market Focus
·
Aug 20